World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
80
Citations
16684
World Ranking
1655
National Ranking
817

Medicine

D-Index
80
Citations
16792
World Ranking
17319
National Ranking
8677

Philip O. Livingston publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Philip O. Livingston sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 193 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Philip O. Livingston D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Philip O. Livingston sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 80 D-Index — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Philip O. Livingston is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research spans multiple fields, including Medicine, Biochemistry, Genetics and Molecular Biology, as well as Immunology and Microbiology. Within these broader disciplines, they have contributed to subfields such as Neurology, Biotechnology, and Immunology.

Their work is focused on several interconnected topics, primarily centered around Neuroblastoma Research and Treatments, Cancer Research and Treatments, and Immunotherapy and Immune Responses. These areas reflect an emphasis on understanding and developing therapeutic approaches to cancer, particularly in immunological contexts.

Livingston has coauthored publications with a number of researchers, including Evan Rosenbaum, Rashmi Chugh, Christopher W. Ryan, Mark Agulnik, and Mohammed Milhem. Collaborative efforts with these colleagues have contributed to the scientific output associated with their profile.

Their recent publication is titled A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery, published in 2022 in the European Journal of Cancer. This paper has accumulated citations, indicating its engagement within the research community.

The European Journal of Cancer is noted as a frequent publication venue for Livingston's work, representing a platform for dissemination of findings related to cancer research.

Best Publications

  • Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides

    Shengle Zhang;Carlos Cordon-Cardo;Helen S. Zhang;Victor E. Reuter

  • Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens

    Shengle Zhang;Helen S. Zhang;Carlos Cordon-Cardo;Victor E. Reuter

  • Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications

    Y.B. Su;Sejean Sohn;Susan E. Krown;Philip O. Livingston

  • Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

    Philip O. Livingston;Edward J. Natoli;Michele Jones Calves;Elisabeth Stockert

  • Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

    S. F. Slovin;G. Ragupathi;S. Adluri;G. Ungers

  • Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

    Philip O. Livingston;Sucharita Adluri;Friedhelm Helling;Tzy-Jyun Yao

  • GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients after Administration with Immunological Adjuvant QS-21

    Helling F;Zhang S;Shang A;Adluri S

  • GD3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines

    Friedhelm Helling;Ann Shang;Michele Calves;Shengle Zhang

  • Synthetic and Immunological Studies on Clustered Modes of Mucin-Related Tn and TF O-Linked Antigens: The Preparation of a Glycopeptide-Based Vaccine for Clinical Trials against Prostate Cancer†

    Scott D. Kuduk;Jacob B. Schwarz;Xiao-Tao Chen;Peter W. Glunz

  • Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

    Teresa Gilewski;Sucharita Adluri;Govindaswami Ragupathi;Shengle Zhang

  • Cancer Biomarkers Defined by Autoantibody Signatures to Aberrant O-Glycopeptide Epitopes

    Hans H. Wandall;Ola Blixt;Mads A. Tarp;Johannes W. Pedersen

  • Expression of Potential Target Antigens for Immunotherapy on Primary and Metastatic Prostate Cancers

    Shengle Zhang;H. S. Zhang;V. E. Reuter;S. F. Slovin

  • Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial

    Teresa Gilewski;Govindaswami Ragupathi;Sonal Bhuta;Lawrence J. Williams

  • Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

    Susan F. Slovin;Govindaswami Ragupathi;Cristina Musselli;Krystyna Olkiewicz

  • Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.

    Govind Ragupathi;Jeffrey R Gardner;Philip O Livingston;David Y Gin

  • Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines

    Philip O. Livingston

  • Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography.

    Wm. Bradley Hamilton;Friedhelm Helling;Kenneth O. Lloyd;Philip O. Livingston

  • Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.

    Govind Ragupathi;Fusataka Koide;Philip O. Livingston;Young Shin Cho

  • A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates

    Richard Lo-Man;Sophie Vichier-Guerre;Ronald Perraut;Edith Dériaud

  • Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

    Wen Jen Hwu;Susan E. Krown;Jennifer H. Menell;Katherine S. Panageas

Frequent Co-Authors

Herbert F. Oettgen
Herbert F. Oettgen Memorial Sloan Kettering Cancer Center
Samuel J. Danishefsky
Samuel J. Danishefsky Columbia University
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research
Kenneth O. Lloyd
Kenneth O. Lloyd Memorial Sloan Kettering Cancer Center
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Gerd Ritter
Gerd Ritter Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in immunology, exploring related healthcare degrees can open diverse career opportunities. Many aspiring healthcare professionals begin with practical nursing programs. Finding programs that are accessible is crucial, and understanding which lpn programs are easiest to get into can help streamline your entry into the nursing field.

As you advance, nurse practitioner degrees offer specialized knowledge and broaden your career options. Those seeking efficient paths often look for clarity on what is the easiest np program, ensuring effective completion while gaining critical skills.

For those drawn to mental health, psychiatric nursing holds a vital role. Pursuing top-quality programs with excellent clinical experiences is essential. Checking out best psychiatric mental health nurse practitioner programs online provides valuable insights into reputable options with strong hands-on training.

Cost is a significant factor for many students, especially for specialized certifications. To manage expenses wisely, it’s beneficial to explore the cheapest pmhnp certificate programs available to find affordable pathways that don’t compromise quality.

Best Scientists Citing Philip O. Livingston

Trending Scientists

Recently Published Articles